...
首页> 外文期刊>European journal of preventive cardiology >Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants
【24h】

Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants

机译:内源性一氧化氮合酶抑制剂不对称二甲基精氨酸(ADMA)的水平和冠心病的风险:基于4713名参与者的荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase by competing with L-arginine. As a result, the expression of nitric oxide decreases and endothelial dysfunction occurs. Studies have evaluated the association between the serum ADMA level and risk of coronary artery disease. However, conflicting results have been obtained.
机译:背景技术不对称二甲基精氨酸(ADMA)是与L-精氨酸竞争的内皮一氧化氮合酶的内源性抑制剂。结果,一氧化氮的表达降低并且发生内皮功​​能障碍。研究评估了血清ADMA水平与冠心病风险之间的关系。但是,已经获得了矛盾的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号